15 Sep 2011 14:15
RNS ANNOUNCEMENT
For immediate release 15 September 2011
THERAKIND PRODUCT UPDATE
EU grants approval for Buccolam®
IPSO Ventures plc ("IPSO"), the creator of commercial value from technology, is pleased to report that further to the announcement on 1st July 2011 regarding Therakind, IPSO's portfolio company, and Buccolam® the European Commission has now granted approval for Buccolam® for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents from 3 months to less than 18 years.
This approval has triggered a further milestone payment for Therakind. Therakind is expected to also receive royalties on sales of this product as Viropharma is now able to actively market this product across Europe.
IPSO has a 36% shareholding in Therakind.
Further information, please contact:
IPSO Ventures plc Nick Rodgers, Chief Executive Officer
| Tel: 020 7921 2990 nick@ipsoventures.com www.ipsoventures.com
|
Allenby Capital Limited (Nominated adviser and broker) Nick Naylor Nick Athanas
| Tel: 020 3328 5656
|
Company description
IPSO Ventures plc is a business creator and active investor in new technologies, principally in the renewable energy and healthcare sector. Its experienced management team focuses on adding commercial value to enable young companies to move forward rapidly.